To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

This is an open label, randomized, active drug comparative, Parallel group, Multi-center, phase IV study. Patients receive candemore tablet or atacand tablet. Initial dose is 4mg/day or 8mg/day. Every 2 weeks, patients take double dose if patients blood pressure is measured SBP ≥ 100mmHg and DBP > 60mmHg. Maximum dose is 16mg/day.

Inclusion criteria

• willing and able to provide written informed consent
• age 20 years or older
• patient with congestive heart failure, taking treatment medicine and NYHA grade II~III
• patient with hypertension, taking treatment medicine or SBP ≥ 140mmHg or DBP ≥ 90mmHg at the screening visit

Exclusion criteria

• Known or suspected secondary hypertension(ex. aortic coactation, primary hyperaldosteronism, renal artery stenosis, pheochromocytoma, cushing syndrome, polycystic renal disease)
• blood creatinine level ≥ 2.5mg/dl
• blood potassium level > 5.5mEq/L
• blood SGOT, SGPT level ≥ maximum normal range X3 or patient with sever hepatic dysfunction, cholestasis
• pregnant or breast-feeding
• premenopausal women not using adequate contraception
• patient has history about hypersensitivity or taboo of investigational product
• patient with lactose intolerance or Lapp lactase deficiency or glucode-galactose malabsorption
• administration of other study drugs within 1 month prior to screening
• history of ischemic heart disease(ex. angina pectoris, myocardial infarction) within the last 3 months
• in investigator's judgement